Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) produced a 19.42% rally since recording the worst price of $0.71. Thanks to the latest 4.8% increase, it now trades at $0.85. Throughout the trading on 6/3/2019, the share price floated between $0.7894 and $0.8799. This company shares are 488.24% off its target price of $5 and the current market capitalization stands at $45.06M. The recent change has given its price a -20.3% deficit over SMA 50 and -81.12% deficit over its 52-week high. The stock witnessed -14.35% declines, -33.76% declines and -54.41% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found TTPH’s volatility during a week at 18.81% and during a month it has been found around 11.37%.

Tetraphase Pharmaceuticals, Inc. (TTPH) Top Holders

Institutional investors currently hold around $17 million or 39.7% in TTPH stock. Look at its top three institutional owners: Blackrock Inc. owns $3.02 million in Tetraphase Pharmaceuticals, Inc., which represents roughly 6.71% of the company’s market cap and approximately 17.79% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 2,341,720 shares of the stock are valued at $1.89 million. The third largest holder is Renaissance Technologies Llc, which currently holds $1.8 million worth of this stock and that ownership represents nearly 4% of its market capitalization.

Tetraphase Pharmaceuticals, Inc. 13F Filings

At the end of March reporting period, 25 institutional holders increased their position in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) by some 2,017,333 shares, 46 decreased positions by 4,689,959 and 23 held positions by 14,275,419. That puts total institutional holdings at 20,982,711 shares, according to SEC filings. The stock grabbed 7 new institutional investments totaling 155,091 shares while 17 institutional investors sold out their entire positions totaling 1,156,746 shares.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Insider Trades

Multiple company employees have indulged in significant insider trading. Tetraphase Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Chief ScientificOfficer Dumas Jacques has sold 7,497 shares of Tetraphase Pharmaceuticals, Inc. (TTPH) in the trading session dated Jan. 08, 2019. These shares are worth $11,995 and were traded at $1.6 each. The SEC filing shows that Dumas Jacques performed a sale of 8,750 shares. The Chief ScientificOfficer disposed these shares by way of transaction on Jan. 30, 2018. The company’s shares were given away at $6.22 per share worth to an income of some $54,425 to the account of Dumas Jacques.

Chief ScientificOfficer, Dumas Jacques, sold 7,167 common shares of Tetraphase Pharmaceuticals, Inc. (TTPH) in the open market. In a transaction dated Jan. 09, 2018, the shares were put up for sale at an average price of $6.21, raking in a sum of $44,507. After this sale, common shares of TTPH are directly owned by the insider, with total stake valued at $.

In the transaction dated Nov. 29, 2017, a great number of shares acquired came courtesy the Director; GAGE L PATRICK added a total of 3,880 shares at an average price of $6.45, amounting to approximately $25,026. The insider now directly owns 38,880 shares worth $33,048.

Tetraphase Pharmaceuticals, Inc. (TTPH) Analyst Guide

Several analysts have released their opinion on Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), with 1 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.2 average brokerage recommendation [T1].